Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: Overlapping distribution with sulfotransferases

Drug Metabolism and Disposition

Volumn 35, Issue 6, 2007, Pages 922-928

  Enokizono, Junichi ^a   Kusuhara, Hiroyuki ^a   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; HYMECROMONE; MINOXIDIL SULFATE; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A2; SULFOTRANSFERASE 1B1; SULFOTRANSFERASE 1D1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG TRANSPORT; INTESTINE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SULFONATION; WESTERN BLOTTING;

ANIMALS; ARYLSULFOTRANSFERASE; ATP-BINDING CASSETTE TRANSPORTERS; ENTEROCYTES; GLUCURONIDES; HYMECROMONE; INTESTINES; MALE; MICE; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; RNA, MESSENGER;

MUS;

EID: 34249095550     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.011239     Document Type: Article

References (39)

1. Adachi Y, Suzuki H, Schinkel AH, and Sugiyama Y (2005) Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol Pharmacol 67:923-928.
2. Alnouti Y and Klaassen CD (2006) Tissue distribution and ontogeny of sulfotransferase enzymes (Sults) in mice. Toxicol Sci 93:242-255.
3. Buhl AE, Waldon DJ, Baker CA, and Johnson GA (1990) Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Investig Dermatol 95:553-557.
4. Chan LM, Lowes S, and Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25-51.
5. Coughtrie MW, Sharp S, Maxwell K, and Innes NP (1998) Biology and function of the reversible sulfation pathway catalysed by human sulfotransferases and sulfatases. Chem-Biol Interact 109:3-27.
6. Doyle LA and Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358.
7. Enokizono J, Kusuhara H, and Sugiyama Y (2007) Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab Dispos 35:209-214.
8. Funk C, Ponelle C, Scheuermann G, and Pantze M (2001) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 59:627-635.
9. Gitlin N, Julie NL, Spurr CL, Lim KN, and Juarbe HM (1998) Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 129:36-38.
10. Glatt H (2000) Sulfotransferases in the bioactivation of xenobiotics. Chem-Biol Interact 129:141-170.
11. Gotoh Y, Suzuki H, Kinoshita S, Hirohashi T, Kato Y, and Sugiyama Y (2000) Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J Pharmacol Exp Ther 292:433-439.
12. Grams B, Harms A, Braun S, Strassburg CP, Manns MP, and Obermayer-Straub P (2000) Distribution and inducibility by 3-methylcholanthrene of family 1 UDP-glucuronosyltransferases in the rat gastrointestinal tract. Arch Biochem Biophys 377:255-265.
13. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, and Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800-807.
14. Johnson BM, Zhang P, Schuetz JD, and Brouwer KL (2006) Characterization of transport protein expression in multidrug resistance-associated protein (Mrp) 2-deficient rats. Drug Metab Dispos 34:556-562.
15. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99:15649-15654.
16. Kaminsky LS and Zhang QY (2003) The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos 31:1520-1525.
17. Kivisto KT, Niemi M, and Fromm MF (2004) Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 18:621-626.
18. Kondo C, Onuki R, Kusuhara H, Suzuki H, Suzuki M, Okudaira N, Kojima M, Ishiwata K, Jonker JW, and Sugiyama Y (2005) Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP/ABCG2). Pharm Res (NY) 22:613-618.
19. Konig J, Nies AT, Cui Y, Leier I, and Keppler D (1999) Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461:377-394.
20. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, et al. (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260.
21. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
22. Mayhew TM (1988) A geometric model for estimating villous surface area in rat small bowel is justified by unbiased estimates obtained using vertical sections. J Anat 161:187-193.
23. Mizuno N, Suzuki M, Kusuhara H, Suzuki H, Takeuchi K, Niwa T, Jonker JW, and Sugiyama Y (2004) Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2- methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab Dispos 32:898-901.
24. Mottino AD, Hoffman T, Jennes L, and Vore M (2000) Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther 293:717-723.
25. Mouly S and Paine MF (2003) P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res (NY) 20:1595-1599.
26. Nagata K and Yamazoe Y (2000) Pharmacogenetics of sulfotransferase. Annu Rev Pharmacol Toxicol 40:159-176.
27. Rost D, Mahner S, Sugiyama Y, and Stremmel W (2002) Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. Am J Physiol 282:G720-G726.
28. Stoffel-Wagner B (2003) Neurosteroid biosynthesis in the human brain and its clinical implications. Ann NY Acad Sci 1007:64-78.
29. Suzuki H and Sugiyama Y (2000) Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 12:3-12.
30. Suzuki M, Suzuki H, Sugimoto Y, and Sugiyama Y (2003) ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278:22644-22649.
31. Tamura HO, Harada Y, Miyawaki A, Mikoshiba K, and Matsui M (1998) Molecular cloning and expression of a cDNA encoding an olfactory-specific mouse phenol sulphotransferase. Biochem J 331 (Pt 3):953-958.
32. Tamura S, Tokunaga Y, Ibuki R, Amidon GL, Sezaki H, and Yamashita S (2003) The site-specific transport and metabolism of tacrolimus in rat small intestine. J Pharmacol Exp Ther 306:310-316.
33. Tanaka Y, Slitt AL, Leazer TM, Maher JM, and Klaassen CD (2005) Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun 326:181-187.
34. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
35. Valenzuela B, Nacher A, Ruiz-Carretero P, Martin-Villodre A, Lopez-Carballo G, and Barettino D (2004) Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol intestinal absorption process. J Pharm Sci 93:1641-1648.
36. van Herwaarden AE, Wagenaar E, Karnekamp B, Merino G, Jonker JW, and Schinkel AH (2006) Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 27:123-130.
37. West AB, Isaac CA, Carboni JM, Morrow JS, Mooseker MS, and Barwick KW (1988) Localization of villin, a cytoskeletal protein specific to microvilli, in human ileum and colon and in colonic neoplasms. Gastroenterology 94:343-352.
38. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, and Brouwer KL (2006) The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 70:2127-2133.
39. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, and Kaminsky LS (1999) Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27:804-809.